Table 3. Clinical efficacy data for targeted agents in development for the treatment of mRCC.
| Study design | Median PFS (months) | P-value | Median OS (months) | P-value | |
|---|---|---|---|---|---|
| Reyorafenib (Eisen et al, 2009) | First line, phase II | 8.3 | NA | NR | NA |
| Tivozanib (Bhargava et al, 2009) | First line, phase II | 11.8 | NA | NR | NA |
| Axitinib (Rixe et al, 2007) | Second line, phase II | 15.7a | NA | 29.9 | NA |
| Axitinib (Rini et al, 2007; Dutcher et al, 2008) | Second line, phase II | 7.4 | NA | NR | NA |
| Refractory to sunitinib and sorafenib | 7.1 | ||||
| Refractory to cytokines and sorafenib | 9 | ||||
| Refractory to sorafenib | 7.7 | ||||
| Linifanib (Tannir et al, 2009) | Second line, phase II | 5.4 | NA | 15.7 | NA |
| Cediranib (Mulders et al, 2009) | First/second line, phase II | 12.1 | 0.017 | NR | NA |
| vs placebo | 2.8 |
Abbreviations: NA=not applicable; NR=not reported; OS=overall survival; PFS=progression-free survival.
a
Reported as time to progression.